Department of ABCT and Our Scholar, Prof. Thomas Leung, Honoured as Awardees for the Inaugural PolyU Patents Achievement Award 2023

We are delighted to announce that the Department of Applied Biology and Chemical Technology at the Hong Kong Polytechnic University (PolyU) and our scholar, Prof. Thomas Leung, have been honoured with the prestigious PolyU Patents Achievement Award 2023. This prestigious recognition celebrates the exceptional achievements of our department and our scholar in the field of intellectual property (IP) filing and innovation.   The PolyU Patents Achievement Award was launched this year to acknowledge and celebrate the remarkable accomplishments of departments and inventors engaged in IP filing. This scheme encompasses two categories of awards, namely the "Top Patents Filing Award" and the "Most Active Patents Filing Award." The former evaluates the IP filing activities over the past five years, while the latter focuses on the IP filing activities within the award year. We are thrilled to share the achievements of our department in both categories.   We are proud to announce the following awards received by our department:   Awards Unit/Awardees Top Patents Filing Award 2023 (Department) Department of Applied Biology and Chemical Technology Most Active Patents Filing Award 2023 (Department) Department of Applied Biology and Chemical Technology Top Patents Filing Award (Inventor) Prof. LEUNG Yun Chung, Thomas   These awards highlight the relentless efforts and innovative spirit of our department members, researchers, and students. We extend our heartfelt congratulations to everyone involved in making these accomplishments possible.   We remain committed to fostering an environment that promotes intellectual property protection, innovation, and technological advancements. The recognition we have received motivates us to continue our pursuit of research excellence and contribute to society through impactful inventions and discoveries.   Once again, congratulations to the Department of ABCT and Prof. Thomas Leung for being honored as awardees for the inaugural PolyU Patents Achievement Award 2023! 

ABCT Retreat 2024

The Department of Applied Biology and Chemical Technology successfully held a departmental retreat in Zhongshan from June 20 to June 21, 2024. The retreat aimed to facilitate the exchange of ideas and promote strategic development within the department. During the retreat, members of the department were divided into groups to allow for in-depth discussions on research sharing. The department also had the privilege of visiting the Zhongshan Institute for Drug Discovery. The visit included a presentation by experts from the institute, followed by a discussion on potential research and development collaborations. This experience has ignited the department's commitment to innovation and opened doors for potential collaborations. The department extends its gratitude to all participants for their active engagement, which contributed to the retreat's success. The outcomes of this retreat will shape the department's strategic plans, fostering further collaboration and ensuring the continued growth and excellence of the department. More details on the event photos can be found at the following link: https://www.polyu.edu.hk/abct/news-and-events/photo-gallery/abct-retreat-2024/    

Seminar on Environmental, Social, and Governance (ESG) and Sustainability

We are pleased to announce that the Hong Kong Council for Testing and Certification and the Hong Kong Association for Testing, Inspection, and Certification jointly organized a successful seminar on environmental, social, and governance (ESG) and sustainability on 11 April 2024. The seminar delved into the challenges faced by businesses in relation to ESG and sustainability, covering key topics such as managing ESG-related data and strategies to meet reporting and regulatory requirements.   Prof. Yu Wing-yiu, Michael, Professor of the Department of Applied Biology and Chemical Technology, was invited as a distinguished speaker at the seminar. Prof. Yu presented on the topic "How the TIC industry helps organizations to achieve and demonstrate Carbon Neutrality." He emphasized that carbon neutrality is grounded in science, and testing and certification bodies serve as independent third-party assessors to ensure objective and accurate results, providing secure quality assurance for various industries.   The seminar generated an enthusiastic response from the participants, with an engaging Q&A session that proved to be highly beneficial for all attendees. The exchange of ideas and knowledge further enriched the discussions on ESG and sustainable practices.

PolyU startup to showcase innovative product at BIO 2024

YnnoMed Limited, a PolyU startup co-founded by Dr Ma Cong, Associate Professor of the Department of Applied Biology and Chemical Technology, is set to make its mark at the highly anticipated BIO International Convention 2024 (BIO 2024) in California next week. As the world's largest and most comprehensive event for biotechnology, the convention provides an ideal platform for YnnoMed to unveil its groundbreaking drug candidates. The drug R&D startup has successfully developed a new class of antibiotic agents and obtained patents in several key regions, including the United States, mainland China, Europe, and Japan. Dr Ma said they target to obtain Food and Drug Administration accreditation for the new product, and to commence clinical trials in 2026. With its potential to revolutionize the field of antibiotic treatments, YnnoMed is poised to make waves at this prestigious event and shape the future of biotechnology.

PolyU research project in new materials and new energy receives funding from RAISe+ Scheme

The Innovation and Technology Commission of the HKSAR government held the Research, Academic and Industry Sectors One-plus (RAISe+) Scheme Signing Ceremony on 28 May 2024 and announced the results of the Scheme’s first round of review. A research project from The Hong Kong Polytechnic University (PolyU) has been awarded RAISe+ funding, showcasing the University’s commitment to promoting excellence in research and innovation, and to creating impact in the community by translating its world-class scientific research into real-world applications. The funded project, titled “Pilot and Mass Production of Next-Generation Composite Current Collectors for Mobility and Energy Storage Batteries (New Materials and New Energy)”, is led by Prof. Zijian ZHENG, Chair Professor of Soft Materials and Devices and Professor of the Department of Applied Biology and Chemical Technology. This project aims to develop an ultrathin, ultralight, flexible and durable composite film to serve as a current collector (CC) for Li-ion batteries (LIBs) and future solid-state Li batteries, aiming at boosting their energy density. The CC is an essential component for the conduction of electrons during the charge/discharge process in LIBs. However, CCs do not contribute to the energy storage in batteries. Therefore, reducing their thickness and weight is an efficient approach to improving the energy density of batteries, a consistent goal in the battery industry over the past decades. Currently, commercial LIBs use copper and aluminum foils as CCs in the anode and the cathode, respectively, the densities of which are thus high. Further reduction of the thickness or weight of metal foils has encountered a bottleneck due to mechanical reliability and processibility. The composite CC developed by the group is 80%~85% lighter and 65%~80% thinner than the current metal foils, with a cost reduction of 40%~60%. Importantly, compared to metal foils, the composite CC better maintains electron and thermal conductivity, chemical and electrochemical stability, and compatibility with various electrode materials. It increases the gravimetric energy density of LIBs by 20%~25% and the volumetric energy density by 9%~12%.  

ABCT Undergraduate Students Embark on an Inspiring Study Trip to Taiwan

A group of 26 ABCT undergraduate students, led by Prof. Zhao Yanxiang, Associate Head of Department of Applied Biology and Chemical Technology and Professor, Dr Ben Ko, Associate Professor, Dr Pele Chong, Dr Gary Cheung, Senior Lecturer, Dr Lam Kim-hung, Lecturer and Dr Chartia Cheung, Lecturer on a study trip to Taiwan from 14 May to 18 May 2024.  The study trip aimed to provide ABCT students with opportunities to expand their horizons, gain exposure to cutting-edge research, and enhance their understanding of the fields of applied biology and chemical technology. It also served as a platform for fostering connections and collaborations with renowned institutions and experts in Taiwan. The group embarked on enlightening visits to the National Health Research Institutes, EirGenix Inc., ACE Biotek Co., Ltd., and the College of Life Sciences and Medicine at National Tsing Hua University. As the students return, they carry with them the valuable insights gained during their time in Taiwan. These experiences will undoubtedly inspire them to excel in their academic pursuits and contribute meaningfully to the field of applied biology and chemical technology.  

2024 Hong Kong-Jiangsu Symposium on Drug Discovery and Development

The "2024 Hong Kong-Jiangsu Symposium on Drug Discovery and Development" successfully concluded on 18 May, 2024, bringing together renowned researchers, scientists, and industry professionals from around the world. Hosted by the Hong Kong Polytechnic University (PolyU) and co-organized with China Pharmaceutical University, the symposium aimed to advance pharmaceutical sciences and foster collaboration in the field of drug discovery and development.   With the theme "Drug Discovery and Development," the symposium addressed global health challenges through innovative research. The event featured a line-up of esteemed speakers, including the distinguished Professor Mark von Itzstein from Griffith University, who shared their expertise and inspired attendees with their ground-breaking work.   Prior to the symposium, Professor Wu Zhaoqiu, Dean of School of Pharmacy and University Distinguished Professor, China Pharmaceutical University and his delegation were invited to visit The Hong Kong Polytechnic University for in-depth academic exchanges and collaborative discussions with the Department of Applied Biology and Chemical Technology from 17 May to 19 May.   During their visit, both sides engaged in in-depth discussions and exchanges regarding pharmacy education, research collaboration, technology transfer, and talent cultivation. The delegation from China Pharmaceutical University and PolyU reached a consensus on future cooperation and signed a preliminary agreement for collaborative exchanges. The preliminary agreement signed between China Pharmaceutical University and PolyU laid the groundwork for future collaborations, particularly in areas such as malignant tumors, fatal cardiovascular and cerebrovascular diseases, metabolic disorders, neurological and psychiatric diseases, immunological disorders, geriatric diseases, rare diseases, as well as the development of First/Best-in-class innovative drugs, novel drug delivery systems, diagnostic reagents, new models and methods, green synthesis, and processes.   Gratitude to the organizing committee, volunteers from PolyU's Department of Applied Biology and Chemical Technology, and generous sponsors, including the Jiangsu-Hong Kong-Macao University Alliance, AstraZeneca Hong Kong Limited, the Hong Kong Science and Technology Park, Medikonia Limited, the Faculty of Science of PolyU, and the State Key Laboratory of Chemical Biology and Drug Discovery. Their support and commitment were acknowledged as vital to the success of the symposium.   Please visit the following links for more details. Event Photos: https://polyu.hk/hLPzp

PolyU Young Innovative Researcher Award 2024

We are delighted to announce that Dr Tian Tian, Assistant Professor, Department of Applied Biology and Chemical Technology, the Hong Kong Polytechnic University (PolyU) has been awarded the PolyU Young Innovative Researcher Award (YIRA) 2024 with his research focus on “The design and development of novel nanoporous materials with enhanced hydrogen storage and delivery capacity”.   PolyU Young Innovative Researcher Award (YIRA) aims to honor young PolyU researchers under the age of 35 who have made outstanding research achievements, contributed to technological advancements, and propelled transformative innovation to address societal problems. The awardees should demonstrate a vision for positive change and provide innovative solutions that shape the future.   Each YIRA awardee will receive research funding support of HK$500,000 and personal cash prize of HK$20,000 as the encouragement for their research novelty and impact.    We extend our heartfelt congratulations to Dr. Tian for this well-deserved recognition. His dedication, innovation, and commitment to advancing the field of nanoporous materials have made a profound impact on the scientific community and hold great promise for a wide range of applications.

PolyU collaborates with Axis Therapeutics to establish joint laboratory for immunotherapy

The Hong Kong Polytechnic University (PolyU) has entered into a formal collaboration with Axis Therapeutics (Axis) to foster cancer immunotherapy research and development, with the aim of improving cancer treatment for patients in Hong Kong. This collaboration will facilitate clinical trials of new T-cell receptor therapy using the newly established clinical Current Good Manufacturing Practice (cGMP) facility at PolyU, which is compliant with the GMP Guide for the Advanced Therapy Products (ATPs), and the development of at least 30 new targeting agents against novel T-cell targets in cancer immunotherapy. An agreement signing ceremony for the establishment of the PolyU-Axis Therapeutics Joint Laboratory for Immunotherapy was held on 18 April. Witnessed by Prof. Wing-tak WONG, PolyU’s Deputy President and Provost; Mr Yonghui WANG, Chairman/President of Xiangxue Pharmaceutical Co Ltd (XPH) and President of Axis; Mr Kejian ZHANG, Chairman of the Strategic Development Committee of XLifeSc; and Dr Johnson Yiu Nam LAU, co-founder of Axis and Adjunct Professor of the Department of Applied Biology and Chemical Technology of PolyU, the agreement was signed by Prof. Larry Ming Cheung CHOW, Head of the Department of Applied Biology and Chemical Technology; and Dr Lun ZENG, CEO of Axis and CEO of XLifeSc. Prof. Wing-tak Wong said that this collaboration would strengthen PolyU’s ongoing efforts in conducting cutting-edge research in life science, especially in the area of translational medicine in cell therapy for treating various diseases including cancers, making contribution to the development of the Greater Bay Area into an innovation hub for cell therapy. Over the years, PolyU researchers have been engaged in the development of three new drugs that have obtained the status of Investigational New Drug (IND) approved by the US Food and Drug Administration (FDA) for clinical trials, all involved in cancer drug treatment. Both small molecules like flavonoids and biologics (arginase enzymes) have been developed at PolyU by the State Key Laboratory of Chemical Biology and Drug Discovery and the Department of Applied Biology and Chemical Technology. Immunotherapy and cell therapy are two of the most important discoveries for treating cancer of the past decade. The 2018 Nobel Prize in Physiology or Medicine was awarded to the discovery of the importance in cancer treatment of T-lymphocyte proteins CTLA-4 and PD-1. This opened a new area of “immune checkpoint therapy” whereby the cancer patient’s own immune system can be reactivated to kill the cancer cells. Another type of immunotherapy is the “adoptive cell therapy” where cancer patient’s own T-cells are collected, genetically modified to give them new function to kill cancers and then expanded in large numbers before being administered back to patients. One example of this therapy is T-cell receptor-engineered T cells (TCR-T), where XPH and its subsidiaries XLifeSc and Axis are the global leaders in this field. Mr Yonghui Wang emphasised that XPH had been committed to the cell therapy programme since 2012. In 2018, Axis entered into an MOU with PolyU to bring cell therapy to cancer patients in Hong Kong. Axis/XLifeSc focuses on utilising the T-cell adoptive immunotherapy technology (TAEST technology) to treat cancers and has engaged in the research into and development of a new generation of anti-tumor TCR-T with a high specificity and affinity for a wide range of malignant solid tumors. Importantly, Axis already has two products with IND approvals in China for soft tissue sarcoma and primary liver cancer. The collaboration with PolyU will further enable Axis to conduct clinical trials in Hong Kong and benefits patients in the city. Moving forward, Axis will collaborate with PolyU in the development of up to 30 further targeting biologics, which could be adapted into novel cell therapy of the future. With the funding support from the University Grants Committee, PolyU established a new clinical cGMP facility on campus which is compliant with the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (PIC/S)’s GMP Guide for the clinical research and development in the ATPs. This cGMP facility will use an isolator for aseptic handling of human stem cells or immune cells for regenerative medicine or immunotherapy clinical trials. It will be also equipped with a training production facility to provide professional training. PolyU researchers will work closely with Axis to unveil new tumour targeting biologics, including TCR-like antibodies, and to explore and develop them for cancer treatment based on cell therapy approach. The Hong Kong Polytechnic University (PolyU) The Hong Kong Polytechnic University (PolyU) aspires to be an innovative world-class university with a strong sense of social responsibility, driven by its motto, “To learn and to apply, for the benefit of mankind”. The University provides the best holistic education to nurture socially responsible “leaders of tomorrow” who possess a strong sense of national identity and a global perspective and pursues impactful innovation and interdisciplinary research to address the world’s most pressing challenges. A robust culture of knowledge transfer and entrepreneurship is a cornerstone of the University, ensuring PolyU’s technologies are transformed into practical real-world applications. The University's unwavering commitment to excellence has earned it international recognition, with PolyU consistently ranking among the top 100 universities worldwide. Based on this solid foundation, the University will continue to make positive contributions in collaboration with its strategic partners for the betterment of Hong Kong, the Nation, and the world. For more information, please visit: www.polyu.edu.hk Guangzhou Xiangxue Pharmaceutical Co. Ltd (XPH) and Axis Therapeutics (Axis) Founded in 1997 and located in Guangzhou Science City, Guangzhou Economic and Technical Development District, XPH is a high-tech enterprise integrating manufacturing, operation and R&D of products including pharmaceuticals, biological medicine, functional food, Chinese medicines and medical devices. XPH is recognised as one of the pharmaceutical enterprises with most development potential in China and has been listed on the Shenzhen Stock Exchange since 2010 (stock code: 300147). XLifeSc, a subsidiary of Xiangxue Pharmaceutical, specializes in high affinity specific T cell adoptive immunotherapy technology (TAEST technology) for researching new generation anti-tumor high specificity and high affinity TCR-T cell products for malignant solid tumors. With a rich pipeline of targets in development and two IND clinical approvals in China and the United States, XLifeSc is positioned as the leading TCR-T cell therapy enterprise in China. In 2018, XLifeSc established Axis Therapeutics in Hong Kong to serve as a platform for overseas expansion with rights for all products and a focus on Hong Kong and international opportunities. For more information, please visit www.xphcn.com and http://www.xlifesc.com/m/about/about.aspx   Media contacts Miss Edith Ma Executive Officer       Department of Applied Biology and Chemical Technology Tel: +852 3400 8606 Email: ho-yin-edith.ma@polyu.edu.hk Ms Jess Fung Manager, Public Affairs Communications and Public Affairs Office Tel: +852 2766 5197 Email: sf-jess.fung@polyu.edu.hk     理大與免疫鍵有限公司合作成立免疫治療聯合實驗室 香港理工大學（理大）與免疫鍵有限公司（Axis）正式合作，共同促進癌症免疫治療研發，改善香港癌症患者的治療成效。是次合作將利用理大新建立、符合現行藥品生產管理規範（cGMP）的先進療法製品（ATP）實驗室和設施進行多種新型「T細胞受體工程T細胞」（TCR-T細胞）療法的臨床試驗。雙方亦將合作開發至少 30 種針對癌症免疫治療中新型 T 細胞標靶的新型抗體等生物製劑。 理大與免疫鍵合作成立「香港理工大學 - 免疫鍵有限公司免疫治療聯合實驗室」的協議簽署儀式於4月18日舉行。 在理大常務及學務副校長黃永德教授、免疫鍵有限公司董事長及香雪製藥董事長王永輝先生、香雪生命科學戰略委員會主任張克堅先生、免疫鍵有限公司聯合創始人及理大應用生物及化學科技學系客座教授劉耀南醫生的見證下，由理大應用生物及化學科技學系系主任周銘祥教授，以及免疫鍵有限公司執行長兼香雪生命科學執行長曾侖醫生代表簽署。 黃永德教授致辭時表示，是次合作將加強理大在生命科學領域的前沿研究，特別是細胞療法轉化醫學方面的努力，以治療包括癌症在內的多種疾病，為促進大灣區發展成為細胞治療創新中心作出貢獻。多年來，理大研究人員已參與三種取得美國食品及藥物管理局（FDA）批准進行臨床試驗（IND）的癌症治療新藥物研究工作。藥物中的黃酮類化合物和生物製劑（精氨酸酶）等小分子是由理大化學生物學及藥物研發國家重點實驗室和應用生物與化學科技學系開發。 免疫療法和細胞療法是過去十年在治療癌症方面的兩大重要發現。2018年諾貝爾生理學或醫學獎得獎項目便是突破性發現 T 淋巴細胞蛋白CTLA-4 和 PD-1在癌症治療中的重要性。這開啟了「免疫檢查點療法」的新領域，透過此療法可重新激活癌症患者自身免疫系統以殺死癌細胞。另一種免疫療法是「過繼性細胞療法」，透過收集癌症患者自身的T細胞進行基因改造，賦予它們殺死癌症的新功能，然後在實驗室內進行大量擴增，再回輸予病人。此療法的其一例子是TCR-T療法，而香雪和子公司香雪生命科學及免疫鍵是此領域的全球領導者之一。 王永輝先生致辭時表示，香雪製藥有限公司自2012年起致力於細胞治療計劃，2018年在港成立免疫鍵，並與理大簽署合作備忘錄，期望為香港癌症患者提供細胞療法。免疫鍵專注利用T細胞過繼免疫治療技術（TAEST技術）來治療癌症，致力於對多種惡性實體腫瘤具高特異性和親和力的新一代抗腫瘤TCR-T研發。目前，免疫鍵有兩款產品於中國獲得臨床試驗批准，分別用於軟組織肉瘤和原發性肝癌的治療。是次與理大的正式合作將進一步加速免疫鍵在香港進行臨床試驗，讓更多本地病人受惠，亦將與理大合作開發多達30種標靶的抗體生物製劑，應用於未來的新型細胞療法。 在大學教育資助委員會資助下，理大於校園設立cGMP設施，其符合國際醫藥品稽查協約組織（PIC/S）就先進療法製品臨床研究和開發指南。該設施將使用隔離器對人類幹細胞或免疫細胞進行無菌處理，用於再生醫學或免疫療法的臨床試驗，並配備專業培訓設施。理大研究人員將與免疫鍵合作，研發更多新型腫瘤標靶生物製劑，包括TCR樣抗體，研究和開發它們用於基於細胞治療方法的癌症治療。 有關香港理工大學 香港理工大學（理大）秉承校訓「開物成務 勵學利民」的精神，矢志成為一所創新型世界一流大學，並以肩負社會重任為宗旨。理大為學生提供優質的全面教育，致力培育具良好國民意識、全球視野與社會責任感的「明日領袖」；同時推動具影響力的創新與跨學科研究，以應對全球最迫切的挑戰。知識轉移與創業文化亦是理大的基石，大學著重研以致用——將所研發的科技轉化為實際應用。理大追求卓越，努力不懈，深得國際認可，持續位居全球百強學府之列。理大將繼續以其雄厚根基，與各界策略夥伴合作，力求造福香港、國家乃至全球。 更多資料，請瀏覽：www.polyu.edu.hk。 有關廣州香雪製藥有限公司、免疫鍵有限公司 廣州市香雪製藥股份有限公司（香雪製藥）成立於1997年，位於廣州黃埔區科學城，擁有自主智慧財產權、自主品牌、自主創新能力的中藥現代化領軍企業和國家級高新技術企業，在中藥資源、智慧中醫、高效能新藥創制、中藥先進製造、生命科學研究、醫療器械等領域的大健康產業形成了全產業鏈集成創新體系。被業界認為是最具發展潛力的製藥企業之一，中國醫藥行業百強企業。香雪製藥於2010年在中國深圳證券交易所首次公開發行股票（IPO）掛牌上市（股票代碼：300147）。 香雪生命科學技術（廣東）有限公司（香雪生命科學XLifeSc）是香雪製藥的子公司，主要利用高親和性特異性T細胞過繼免疫治療技術（TAEST技術），開展針對惡性腫瘤實體瘤進行新一代抗腫瘤高強特異性和高親和性T細胞免疫治療TCR-T細胞產品的研究，香雪生命科學靶點豐富的在研管線，在中國和美國擁有兩個IND臨床批件，是中國TCRT細胞治療頭部企業。 2018年，香雪生命科學在香港成立子公司「免疫鍵有限公司」，作為海外拓展平台，擁有所有產品的海外權利，並專注於香港和國際機會。 更多資料，請瀏覽﹕ www.xphcn.com 及 http://www.xlifesc.com/m/about/about.aspx。   傳媒查詢 馬浩然女士 行政主任 電話﹕+852 3400 8606 電郵：ho-yin-edith.ma@polyu.edu.hk 馮秀芳女士 公共事務經理 電話﹕+852 2766 5197 電郵﹕sf-jess.fung@polyu.edu.hk  

PolyU wins record-breaking number of awards at International Exhibition of Inventions Geneva

Impactful innovations from The Hong Kong Polytechnic University (PolyU) won a record-breaking number of accolades at the 49th International Exhibition of Inventions Geneva (Geneva Inventions Expo), a widely recognised annual event devoted exclusively to invention. 43 PolyU innovations seized 45 accolades, including two Special Prizes, five Gold Medals with Congratulations of the Jury, 18 Gold Medals, 13 Silver Medals and seven Bronze Medals. Among them, 19 were developed under the InnoHK research centres led by PolyU in collaboration with top research institutions around the world. This achievement underscores the commitment of the PolyU community, encompassing scholars, students and alumni, to embracing research breakthroughs. Prof. Christopher CHAO, PolyU Vice President (Research and Innovation), extended his congratulations to the University’s winning teams and stated, “I am thrilled about the exceptional accomplishments of PolyU’s research teams at the Geneva Inventions Expo this year. The results are truly encouraging and serve as a testament to the outstanding research capabilities of our scholars and experts. The international recognition will inspire them to continue pursuing excellence, not only in basic research but also in translating their research outcomes into positive impacts for the benefit of Hong Kong, our Nation, and the world.” This year, PolyU’s award-winning projects span the fields of life sciences and healthcare, renewable energy, new energy vehicles, materials and sensing technology, civil engineering, food science, and vision and eye health. These projects demonstrate the University’s dedication to improving human health and lives and contributing to sustainable development. PolyU is at the forefront globally of driving innovation and entrepreneurship. Among the PolyU award-winning teams, 10 are PolyU-nurtured startups, some of which were founded by the University’s scholars. To-date, the University has trained over 7,600 entrepreneurs, including researchers, alumni and students, and nurtured nearly 500 active startups PolyU innovations and research projects have also garnered close to 400 international and local awards. The 49th Geneva Inventions Expo attracted 1,035 entries from 38 countries and regions. The award-winning projects of PolyU ABCT are listed below.  To learn more about these impactful projects, please refer to the Appendix or visit the website of the PolyU Knowledge Transfer and Entrepreneurship Office. Project Principal Investigator(s) Award(s) MicroFish: A Lab-on-a-chip for On-site Detection of Microbial Contamination and Pollutants Dr CHUA Song Lin Assistant Professor, Department of Applied Biology and Chemical Technology; Co-founder, Microfish Limited (a PolyU academic-led startup) Dr LIU Yang Sylvia GBA Startup Postdoctoral Fellow, Department of Applied Biology and Chemical Technology; Co-founder, Microfish Limited (a PolyU academic-led startup) Gold Medal 3D Printed Triply Periodic Minimal Surface (TPMS) Bone Scaffolds Dr ZHAO Xin Associate Professor, Department of Applied Biology and Chemical Technology; Founder, ReNew Biotechnology Limited (a PolyU academic-led startup) Gold Medal Autophagy-targeting Peptidomimetics as Novel Cancer Therapeutics Prof. ZHAO Yanxiang Associate Head, Departmental Learning and Teaching Committee Chair, and Professor, Department of Applied Biology and Chemical Technology Gold Medal Transcutaneous Electrical Nerve Stimulation (TENS) Hat to Limit Dementia Progression Dr SETO Sai-wang Associate Director, Research Centre for Chinese Medicine Innovation; Assistant Professor, Department of Food Science and Nutrition Prof. Samuel LO Honorary Professor, Department of Applied Biology and Chemical Technology Bronze Medal     理大於日內瓦發明展再創佳績 歷年獲獎數量最多 香港理工大學（理大）於全球享負盛名的第49屆瑞士日內瓦「國際發明展」（發明展）突破歷年成績，勇奪多項殊榮。43個參賽項目成功奪得45個獎項，包括兩個特別大獎、五個評審團嘉許金獎、18個金獎、13個銀獎，以及七個銅獎，當中19個獲獎項目為理大於InnoHK創新香港研發平台研究中心與其他國際頂尖院校共同開發的研究成果。是次佳績充分肯定理大學者、學生及校友在探索、開創和追求科研突破的努力。 理大副校長（研究及創新）趙汝恒教授恭賀理大得獎團隊，並說﹕「理大今年於日內瓦國際發明展奪得多個獎項，成績令人鼓舞。理大學者專家擁有卓越的科研實力，是次獲獎將激勵他們在科研成果轉化和基礎研究上精益求精，推動大學繼續以創新科研，為香港、國家，以至全球帶來正面的影響。」 今年理大獲獎項目涵蓋生物科學與醫療保健、可再生能源、新能源汽車、材料與傳感技術、土木工程、食品科學、視力健康等不同範疇，以卓越科研改善人類的健康和生活，為可持續發展作出貢獻。理大是推動創新創業的先驅，獲獎團隊中，包括10間理大初創公司，其中部分由理大學者創立。理大透過不同創業支援計劃，至今培育了逾7,600位創業家，包括理大學者、研究人員、校友和學生等；活躍的理大初創企業亦近500間，並獲得近400項國際和本地奬項。 今屆發明展吸引1,035個來自38個國家及地區的項目參展，香港理工大學應用生物及化學科技學系的獲獎項目如下所列。，詳情載於附件或可瀏覽理大知識轉移及創業處網頁。   得獎項目 發明者 獎項 漁芯：即時檢測微生物和污染物的芯片實驗室 蔡松霖博士 理大應用生物及化學科技學系助理教授、理大學者領導初創「漁芯有限公司」聯合創始人 劉揚博士 理大應用生物及化學科技學系創新應用博士後、理大學者領導初創「漁芯有限公司」聯合創始人 金獎 維打印三週期極小曲面（TPMS）骨支架 趙昕博士 理大應用生物及化學科技學系副教授、理大學者領導初創「瑞新生物科技有限公司」創始人 金獎 癌症突破性新療法：靶向自噬的多肽模擬物 趙燕湘教授 理大應用生物及化學科技學系副系主任、系教學委員會主席兼教授 金獎 頭戴式經皮神經電刺激（TENS）裝置改善認知障礙症患者的認知功能 司徒世宏博士 理大中醫藥創新研究中心副主任、食品科學及營養學系助理教授 盧俊立教授 理大應用生物及化學科技學系名譽教授 銅獎